Literature DB >> 24168656

microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β1 up-regulation.

Javier Beaumont1, Begoña López1, Nerea Hermida1, Blanche Schroen2, Gorka San José1, Stephane Heymans2, Félix Valencia3, Juan José Gómez-Doblas3, Eduardo De Teresa3, Javier Díez, Arantxa González1.   

Abstract

miRNAs (microRNAs) have been shown to play a role in myocardial fibrosis. The present study was designed to analyse whether alterations in miRNA expression contribute to the progression of myocardial fibrosis in AS (aortic valve stenosis) patients through up-regulation of the pro-fibrotic factor TGF-β1 (transforming growth factor-β type 1). Endomyocardial biopsies were obtained from 28 patients with severe AS, and from the necropsies of 10 control subjects. AS patients presented increased myocardial CVF (collagen volume fraction) and TGF-β1 compared with the controls, these parameters being correlated in all patients. Patients were divided into two groups by cluster analysis according to their CVF: SF (severe fibrosis; CVF >15%; n=15) and non-SF (CVF ≤15%; n=13). TGF-β1 was increased in patients with SF compared with those with non-SF. To analyse the involvement of miRNAs in SF, the miRNA expression profile of 10 patients (four with non-SF and six with SF) was analysed showing that 99 miRNAs were down-regulated and 19 up-regulated in the SF patients compared with the non-SF patients. Those miRNAs potentially targeting TGF-β1 were validated by real-time RT (reverse transcription)-PCR in the whole test population, corroborating that miR-122 and miR-18b were down-regulated in patients with SF compared with those with non-SF and the control subjects. Additionally, miR-122 was inversely correlated with the CVF, TGF-β1 and the TGF-β1-regulated PCPE-1 (procollagen C-terminal proteinase enhancer-1) in all patients. Experiments in human fibroblasts demonstrated that miR-122 targets and inhibits TGF-β1. In conclusion, for the first time we show that myocardial down-regulation of miR-122 might be involved in myocardial fibrosis in AS patients, probably through TGF-β1 up-regulation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24168656     DOI: 10.1042/CS20130538

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  35 in total

1.  The long noncoding RNA Wisper controls cardiac fibrosis and remodeling.

Authors:  Rudi Micheletti; Isabelle Plaisance; Brian J Abraham; Alexandre Sarre; Ching-Chia Ting; Michael Alexanian; Daniel Maric; Damien Maison; Mohamed Nemir; Richard A Young; Blanche Schroen; Arantxa González; Samir Ounzain; Thierry Pedrazzini
Journal:  Sci Transl Med       Date:  2017-06-21       Impact factor: 17.956

Review 2.  MicroRNA: A new therapeutic strategy for cardiovascular diseases.

Authors:  Saheli Samanta; Sathyamoorthy Balasubramanian; Sheeja Rajasingh; Urmi Patel; Anuradha Dhanasekaran; Buddhadeb Dawn; Johnson Rajasingh
Journal:  Trends Cardiovasc Med       Date:  2016-03-03       Impact factor: 6.677

Review 3.  Noncoding RNA as regulators of cardiac fibrosis: current insight and the road ahead.

Authors:  Hui Tao; Jing-Jing Yang; Wei Hu; Kai-Hu Shi; Zi-Yu Deng; Jun Li
Journal:  Pflugers Arch       Date:  2016-01-20       Impact factor: 3.657

4.  Differentially expressed microRNAs in the corpus cavernosum from a murine model with type 2 diabetes mellitus-associated erectile dysfunction.

Authors:  Feng Pan; Jinwei You; Yuan Liu; Xuefeng Qiu; Wen Yu; Jiehua Ma; Lianjun Pan; Aixia Zhang; Qipeng Zhang
Journal:  Mol Genet Genomics       Date:  2016-09-28       Impact factor: 3.291

Review 5.  Noncoding RNAs and myocardial fibrosis.

Authors:  Thomas Thum
Journal:  Nat Rev Cardiol       Date:  2014-09-09       Impact factor: 32.419

6.  Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.

Authors:  Carlos J Pirola; Tomas Fernández Gianotti; Gustavo O Castaño; Pablo Mallardi; Julio San Martino; María Mora Gonzalez Lopez Ledesma; Diego Flichman; Faridodin Mirshahi; Arun J Sanyal; Silvia Sookoian
Journal:  Gut       Date:  2014-06-27       Impact factor: 23.059

7.  MiR-216a accelerates proliferation and fibrogenesis via targeting PTEN and SMAD7 in human cardiac fibroblasts.

Authors:  Jinsong Tao; Jingyi Wang; Chunyu Li; Weiwei Wang; Hao Yu; Jinhui Liu; Xiangqing Kong; Yan Chen
Journal:  Cardiovasc Diagn Ther       Date:  2019-12

8.  Mir-1, miR-122, miR-132, and miR-133 Are Related to Subclinical Aortic Atherosclerosis Associated with Metabolic Syndrome.

Authors:  Agnė Šatrauskienė; Rokas Navickas; Aleksandras Laucevičius; Tomas Krilavičius; Rūta Užupytė; Monika Zdanytė; Ligita Ryliškytė; Agnė Jucevičienė; Paul Holvoet
Journal:  Int J Environ Res Public Health       Date:  2021-02-04       Impact factor: 3.390

9.  Cardiovascular and Cerebrovascular Disease Associated microRNAs Are Dysregulated in Placental Tissues Affected with Gestational Hypertension, Preeclampsia and Intrauterine Growth Restriction.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Lucie Hympanova; Ladislav Krofta
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

10.  Circulating microRNA Profiling Needs Further Refinement Before Clinical Use in Patients With Aortic Stenosis.

Authors:  Sean Coffey; Michael J A Williams; L Vicky Phillips; Gregory T Jones
Journal:  J Am Heart Assoc       Date:  2015-08-24       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.